AxoGen Secures Avance Approval, Boosting Coverage and Reimbursement

Got story updates? Submit your updates here. ›

AxoGen executives say a newly secured Biologics License Application (BLA) approval has preserved the company's ability to serve patients across a broad range of peripheral nerve repair needs, while also helping address remaining reimbursement and coverage barriers that have affected adoption. The FDA-approved label allows AxoGen to continue its work without limitations, and the BLA approval provides a regulatory foundation to support continued market development and efforts to establish nerve care as a standard of care.

Why it matters

The BLA approval positions AxoGen's Avance product as a reference product with a period of exclusivity, making it difficult for competitors to enter the market. It also addresses previous concerns from payers that viewed the product as 'experimental' prior to the BLA, paving the way for increased insurance coverage. Additionally, changes to CMS reimbursement in the outpatient setting are expected to provide more economic support for nerve care procedures.

The details

AxoGen CEO Mike Dale said the BLA-approved label allows the company to continue its work and does not limit use by nerve type, preserving its ability to serve sensory, motor, and mixed nerves. The BLA approval also provides a regulatory foundation to support continued market development and efforts to establish nerve care as a standard of care. Regarding exclusivity, Dale said AxoGen has been advised that another allograft product cannot enter the market during the exclusivity window, and the practical hurdles to entering the space are substantial, likely taking at least a decade. On the insurance coverage front, Dale said three primary commercial insurers still do not provide coverage for Avance, but the BLA has addressed their previous view of the product as 'experimental.' AxoGen has made formal submissions and requests for reconsideration, and is now waiting for responses aligned with each payer's annual review cycle. CMS also made a change to outpatient reimbursement, separating nerve care services from unrelated low-cost procedures and creating a dedicated nerve code with payments AxoGen views as appropriate. While much nerve care will remain inpatient, Dale expects outpatient settings to become an additional opportunity over time.

• The FDA approved AxoGen's Biologics License Application (BLA) in March 2026.

What they’re saying

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.